Table 2

Efficacy of therapy

ParameterThalidomide (N = 44)Lenalidomide (N = 41)Lenalidomide plus prednisoneP
Response    .06 
    Overall, median (%) [95% CI] 7 (16) [7-30] 14 (34) [20-51] 15 (38) [23-54]  
    CR, median (%) [95% CI] 1 (2) [0-12] 2 (5) [1-17] 2 (5) [1-7]  
    PR, median (%) [95% CI] 1 (2) [0-12] 5 (12) [4-26] 4 (10) [3-24]  
    CI, median (%) [95% CI]* 5 (12) [4-25] 7 (17) [7-32] 9 (23) [11-38]  
    Hemoglobin level, median (%) [95% CI]  
    Platelet count, median (%) [95% CI] NA  
    ANC, median (%) [95% CI] NA NA  
    Spleen, median (%) [95% CI] NA  
Median follow-up (range), mo 116 (16-121) 57 (5-67) 42 (6 to ≥49) < .0001 
Median response duration (range), mo 13 (4-30) 7 (1-41) 34 (1 to ≥49) .042 
Median time to first response (range), wk 8 (3-15) 17 (2-29) 11 (2-45) .0066 
Median time to best response (range), wk 8 (3-32) 18 (2-39) 14 (2-79) .0138 
ParameterThalidomide (N = 44)Lenalidomide (N = 41)Lenalidomide plus prednisoneP
Response    .06 
    Overall, median (%) [95% CI] 7 (16) [7-30] 14 (34) [20-51] 15 (38) [23-54]  
    CR, median (%) [95% CI] 1 (2) [0-12] 2 (5) [1-17] 2 (5) [1-7]  
    PR, median (%) [95% CI] 1 (2) [0-12] 5 (12) [4-26] 4 (10) [3-24]  
    CI, median (%) [95% CI]* 5 (12) [4-25] 7 (17) [7-32] 9 (23) [11-38]  
    Hemoglobin level, median (%) [95% CI]  
    Platelet count, median (%) [95% CI] NA  
    ANC, median (%) [95% CI] NA NA  
    Spleen, median (%) [95% CI] NA  
Median follow-up (range), mo 116 (16-121) 57 (5-67) 42 (6 to ≥49) < .0001 
Median response duration (range), mo 13 (4-30) 7 (1-41) 34 (1 to ≥49) .042 
Median time to first response (range), wk 8 (3-15) 17 (2-29) 11 (2-45) .0066 
Median time to best response (range), wk 8 (3-32) 18 (2-39) 14 (2-79) .0138 

ANC indicates absolute neutrophil count; and CI, confidence interval.

*

Patients could have CI involving several lineages.

or Create an Account

Close Modal
Close Modal